ALB and hepatocellular carcinoma: More recently, a multicenter Italian study reported that the albumin–bilirubin (ALBI) score, originally developed for liver function evaluation in HCC patients, was independently associated with de novo HCC (HR = 2.35, p = 0.038) in patients with HCV-related cirrhosis receiving DAA therapy [14].